Cancer Family
Myeloid Neoplasm
CI-CAN-00000279Explore in graph →
HematologicNon-malignant1,103 active trials29 approved drugs653 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000279Explore in graph →
Clinical trials
4,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02889003 | Second STOP After Pioglitazone Priming in CML Patients(PIO2STOP) | recruiting | Phase 2 | 26 | Versailles HospitalOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT04877522 | Asciminib Roll-over Study | recruiting | Phase 4 | 347 | Novartis PharmaceuticalsINDUSTRY | 29 | Jul 6, 2026 | clinicaltrials |
| NCT05074355 |
| Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms |
| recruiting |
| Phase 2 |
| 40 |
| University Health Network, TorontoOTHER |
| 1 |
| Jul 6, 2026 |
| clinicaltrials |
| NCT05805605 | Allo HSCT Using RIC and PTCy for Hematological Diseases | recruiting | Phase 2 | 56 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT06697600 | A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers(UR-GOAL RCT) | recruiting | N/A | 1,020 | University of RochesterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07019155 | Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants | recruiting | — | 510 | National Cancer Institute (NCI)NIH | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07548983 | Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation | recruiting | Phase 1 | 40 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT06234904 | Study of IBR733 Cell Injection in Acute Myeloid Leukemia | recruiting | Phase 1 | 18 | Imbioray (Hangzhou) Biomedicine Co., Ltd.INDUSTRY | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07304011 | Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent | recruiting | Phase 2 | 28 | University of California, DavisOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07680868 | Caris Chromoseq Data Collection | recruiting | — | 300 | Caris Science, Inc.INDUSTRY | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07680933 | Orelabrutinib Combined With Standard Immunochemotherapy With or Without Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) for Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL) | recruiting | Phase 2 | 30 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT04050280 | CLAG-GO for Patients With Persistent, Relapsed or Refractory AML | recruiting | Phase 2 | 39 | University of Maryland, BaltimoreOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04064060 | A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials | recruiting | Phase 3 | 665 | CelgeneINDUSTRY | 22 | Jul 1, 2026 | clinicaltrials |
| NCT06996119 | Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant | recruiting | Phase 1 | 15 | City of Hope Medical CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07007052 | Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients(TAGVEN) | recruiting | Phase 2 | 33 | French Innovative Leukemia OrganisationOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07292272 | Halt Aging in Survivors of Blood Cancers(HALTAging-1) | recruiting | N/A | 180 | University of NebraskaOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06357182 | Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia | recruiting | Phase 1 | 30 | OHSU Knight Cancer InstituteOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07675967 | Clonal Hematopoiesis Chemotherapy and Radiation Effects Study(CH CARE) | recruiting | — | 5,000 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT01137825 | Registry of Older Patients With Cancer | recruiting | — | 3,000 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06815003 | Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning | recruiting | Phase 2 | 35 | City of Hope Medical CenterOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06802315 | Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)(BMT-13) | recruiting | Phase 2 | 38 | University of Illinois at ChicagoOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT03314974 | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | recruiting | Phase 2 | 300 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT04869683 | Biocollection in MyeloDysplastic Syndrome (P-MDS)(P-MDS) | recruiting | N/A | 150 | University Hospital, BrestOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07668557 | Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia(ICG415-AML-01) | recruiting | Phase 1 | 18 | iCell Gene TherapeuticsINDUSTRY | 1 | Jun 25, 2026 | clinicaltrials |
| NCT04068597 | Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies | recruiting | Phase 1 / Phase 2 | 250 | CellCentric Ltd.INDUSTRY | 5 | Jun 24, 2026 | clinicaltrials |
| NCT07445893 | A Clinical Study of Gecacitinib Combined With Pegylated Interferon in Patients With PV | recruiting | N/A | 30 | Duan MinghuiOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT06551584 | Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT | recruiting | Phase 1 | 24 | Stanford UniversityOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT03128034 | 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia | recruiting | Phase 1 / Phase 2 | 75 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT03670966 | 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome | recruiting | Phase 1 / Phase 2 | 30 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT04581512 | Study to Evaluate the Safety and Tolerability of EP0042 | recruiting | Phase 1 / Phase 2 | 70 | Ellipses PharmaINDUSTRY | 3 | Jun 22, 2026 | clinicaltrials |
| NCT05549661 | Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms | recruiting | Phase 1 | 25 | Mayo ClinicOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT05756777 | A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML) | recruiting | Phase 1 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT06017258 | A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia | recruiting | Phase 1 | 15 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07080970 | Observational Study on APL-like aCute Myeloid Leukemia: disTInct Phenotype and Early VAscular complicaTions(ACTIVATE) | recruiting | — | 220 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07356154 | A Study of Revumenib and Mezigdomide in People With Leukemia | recruiting | Phase 1 / Phase 2 | 52 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT06707493 | Ivosidenib as Post-HSCT Maintenance for AML | recruiting | Phase 2 | 75 | Massachusetts General HospitalOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT03050268 | Familial Investigations of Childhood Cancer Predisposition(SJFAMILY) | recruiting | — | 1,500 | St. Jude Children's Research HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT03113643 | SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | recruiting | Phase 1 | 72 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT04024761 | A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation | recruiting | Phase 1 | 50 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT06138587 | Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation | recruiting | Phase 1 | 15 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07011004 | A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia | recruiting | Phase 1 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT03280888 | Relevance of Peripheral Cells in the Pathophysiology of Chronic Myelomonocytic Leukemia (CMML) | recruiting | — | 50 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07651878 | Phase I Trial of Vididencel in CML-CP Patients With MRD Under TKI Treatment | recruiting | Phase 1 | 24 | MendusINDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT02074839 | Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation | recruiting | Phase 1 | 291 | Institut de Recherches Internationales ServierOTHER | 2 | Jun 15, 2026 | clinicaltrials |
| NCT05768932 | BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 260 | SillaJen, Inc.INDUSTRY | 2 | Jun 15, 2026 | clinicaltrials |
| NCT04047641 | Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | recruiting | Phase 1 / Phase 2 | 80 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05834244 | A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML) | recruiting | Phase 1 | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05915208 | Histiocytic Disorder Follow-up Study | recruiting | — | 6,000 | University of Alabama at BirminghamOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06448013 | A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia | recruiting | Phase 1 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 6, 2026source: clinicaltrials